文献速递流行病学与生物统计临床试验与 GCP

盐皮质激素受体拮抗剂在心力衰竭中的应用:一项个体患者水平Meta分析

Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis.
PubMed 文献 · Lancet · 2024-09-01

这项预设的个体患者水平Meta分析纳入RALES、EMPHASIS-HF、TOPCAT和FINEARTS-HF四项试验共13846例心力衰竭患者,评估盐皮质激素受体拮抗剂(MRA)在射血分数降低(HFrEF)及轻度降低或保留(HFmrEF/HFpEF)心衰中的疗效与安全性。结果显示MRA降低心血管死亡或心衰住院复合风险(HR 0.77,95%CI 0.72-0.83),HFrEF获益大于HFmrEF/HFpEF(交互作用P=0.0012),高钾血症风险增加但严重高钾血症发生率低。

要点

  • MRA降低心衰患者心血管死亡或心衰住院复合风险(HR 0.77,95%CI 0.72-0.83)。
  • HFrEF获益大于HFmrEF/HFpEF(交互作用P=0.0012;HR 0.66 vs 0.87)。
  • MRA使高钾血症风险加倍(OR 2.27),低钾血症风险减半(OR 0.51)。

核心结论

  • 甾体类MRA降低HFrEF患者心血管死亡或心衰住院风险,非甾体类MRA降低HFmrEF或HFpEF患者该风险。

研究设计与样本

  • 预设的个体患者水平Meta分析,纳入RALES(螺内酯)和EMPHASIS-HF(依普利酮)试验的HFrEF患者,以及TOPCAT(螺内酯)和FINEARTS-HF(非奈利酮)试验的HFmrEF或HFpEF患者,共13846例。
  • 主要结局为首次心衰住院或心血管死亡的复合终点时间,并评估各组分、总心衰住院和全因死亡及安全性指标。
  • 研究注册于PROSPERO,CRD42024541487。

主要发现

  • MRA降低心血管死亡或心衰住院复合风险(HR 0.77,95%CI 0.72-0.83)。
  • 试验与治疗交互作用有统计学意义(交互作用P=0.0012),HFrEF疗效大于HFmrEF或HFpEF(HR 0.66 [95%CI 0.59-0.73] vs 0.87 [95%CI 0.79-0.95])。
  • 心衰住院在HFrEF试验(HR 0.63,95%CI 0.55-0.72)和HFmrEF或HFpEF试验(HR 0.82,95%CI 0.74-0.91)中均显著降低。
  • 心血管死亡在HFrEF试验中降低(HR 0.72,95%CI 0.63-0.82),在HFmrEF或HFpEF试验中未显著降低(HR 0.92,95%CI 0.80-1.05)。
  • 全因死亡在HFrEF试验中降低(HR 0.73,95%CI 0.65-0.83),在HFmrEF或HFpEF试验中未显著降低(HR 0.94,95%CI 0.85-1.03)。

关键数值与推荐

  • 与安慰剂相比,MRA使高钾血症风险加倍(OR 2.27,95%CI 2.02-2.56),严重高钾血症(血钾>6.0 mmol/L)发生率为2.9% vs 1.4%。
  • 低钾血症(血钾<3.5 mmol/L)风险减半(OR 0.51,95%CI 0.45-0.57;7% vs 14%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Mineralocorticoid receptor antagonists (MRAs) reduce hospitalisations and death in patients with heart failure and reduced ejection fraction (HFrEF), but the benefit in patients with heart failure and mildly reduced ejection fraction (HFmrEF) or heart failure and preserved ejection fraction (HFpEF) is unclear. We evaluated the effect of MRAs in four trials that enrolled patients with heart failure across the range of ejection fraction. METHODS: This is a prespecified, individual patient level meta-analysis of the RALES (spironolactone) and EMPHASIS-HF (eplerenone) trials, which enrolled patients with HFrEF, and of the TOPCAT (spironolactone) and FINEARTS-HF (finerenone) trials, which enrolled patients with HFmrEF or HFpEF. The primary outcome of this meta-analysis was a composite of time to first hospitalisation for heart failure or cardiovascular death. We also estimated the effect of MRAs on components of this composite, total (first or repeat) heart failure hospitalisations (with and without cardiovascular deaths), and all-cause death. Safety outcomes were also assessed, including serum creatinine, estimated glomerular filtration rate, serum potassium, and systolic blood pressure. An interaction between trials and treatment was tested to examine the heterogeneity of effect in these populations. This study is registered with PROSPERO, CRD42024541487. FINDINGS: 13 846 patients were included in the four trials. MRAs reduced the risk of cardiovascular death or heart failure hospitalisation (hazard ratio 0·77 [95% CI 0·72-0·83]). There was a statistically significant interaction by trials and treatment (p for interaction=0·0012) due to the greater efficacy in HFrEF (0·66 [0·59-0·73]) compared with HFmrEF or HFpEF (0·87 [0·79-0·95]). We observed significant reductions in heart failure hospitalisation in the HFrEF trials (0·63 [0·55-0·72]) and the HFmrEF or HFpEF trials (0·82 [0·74-0·91]). The same pattern was observed for total heart failure hospitalisations with or without cardiovascular death. Cardiovascular death was reduced in the HFrEF trials (0·72 [0·63-0·82]) but not in the HFmrEF or HFpEF trials (0·92 [0·80-1·05]). All-cause death was also reduced in the HFrEF trials (0·73 [0·65-0·83]) but not in the HFmrEF or HFpEF trials (0·94 [0·85-1·03]). With an MRA, the risk of hyperkalaemia was doubled compared with placebo (odds ratio 2·27 [95% CI 2·02-2·56]), but the incidence of serious hyperkalaemia (serum potassium >6·0 mmol/L) was low (2·9% vs 1·4%); the risk of hypokalaemia (potassium <3·5 mmol/L) was halved (0·51 [0·45-0·57]; 7% vs 14%). INTERPRETATION: Steroidal MRAs reduce the risk of cardiovascular death or heart failure hospitalisation in patients with HFrEF and non-steroidal MRAs reduce this risk in patients with HFmrEF or HFpEF. FUNDING: None.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Jhund PS, Talebi A, Henderson AD, et al. Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis. Lancet. 2024. PMID: 39232490. doi:10.1016/S0140-6736(24)01733-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。